07.02.2013 - US biotech Biogen Idec has bagged full rights to Elan's Multiple Sclerosis blockbuster Tysabri in a US$3.25bn deal.
The news came following rumours that Biogen Idec plans to take over the Irish drugmaker, after its Alzheimer antibody bapineuzumab failed in a Phase III study. Biogen instead decided to take full ownership of the currently most effective therapy for the relapsing form of multiple sclerosis (MS) for US$3.25bn. Under the terms of the agreement, Elan will receive 12% of global net sales for the first year after the deal is completed. After that, Elan will receive 18% on up to US$2bn of global net sales and 25% on any sales over that amount. Last year Tysabri made US$1.6bn (+8%) but an MAA as first line treatment filed last month is expected to further boost sales. "The restructuring of this business collaboration provides Elan with significant strategic flexibility," said the company's CEO Kelly Martin.
With the deal, Biogen Idec strengthens its MS drug portfolio after having co-marketed the antibody Tysabri with Elan since 2004. The US company filed for US approval of its oral dimethyl-fumarate BG-12 (Tecfidera) last year. Biogen could then offer the Interferon beta-1a Avonex alongside with BG-12 and Tysabri strenghtening the company's position in the lucrative MS market against Novartis, Teva, Merck KGaA and Bayer.
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more